

ABBOTT LABORATORIES  
Form 8-K  
May 04, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 29, 2016**

**Abbott Laboratories**

(Exact name of registrant as specified in its charter)

**Illinois**  
(State or Other Jurisdiction of  
Incorporation)

**1-2189**  
(Commission File Number)

**36-0698440**  
(IRS Employer Identification  
No.)

**100 Abbott Park Road**  
**Abbott Park, Illinois 60064-6400**

(Address of principal executive offices)(Zip Code)

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

Registrant's telephone number, including area code: **(224) 667-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Abbott Laboratories held its Annual Meeting of Shareholders on April 29, 2016. The following is a summary of the matters voted on at that meeting.

(1) The shareholders elected Abbott's entire Board of Directors. The persons elected to Abbott's Board of Directors and the number of shares cast for, the number of shares withheld, and the number of broker non-votes, with respect to each of these persons, were as follows:

| Name                   | Votes For     | Votes Withheld | Broker Non-Votes |
|------------------------|---------------|----------------|------------------|
| Robert J. Alpern, M.D. | 1,086,257,937 | 9,089,950      | 205,672,438      |
| Roxanne S. Austin      | 1,061,009,241 | 34,338,646     | 205,672,438      |
| Sally E. Blount, Ph.D. | 1,086,323,743 | 9,024,144      | 205,672,438      |
| W. James Farrell       | 1,072,879,916 | 22,467,971     | 205,672,438      |
| Edward M. Liddy        | 1,073,198,631 | 22,149,256     | 205,672,438      |
| Nancy McKinstry        | 1,087,919,410 | 7,428,477      | 205,672,438      |
| Phebe N. Novakovic     | 1,086,302,380 | 9,045,507      | 205,672,438      |
| William A. Osborn      | 1,070,588,346 | 24,759,541     | 205,672,438      |
| Samuel C. Scott III    | 1,075,564,931 | 19,782,956     | 205,672,438      |
| Glenn F. Tilton        | 1,056,326,280 | 39,021,607     | 205,672,438      |
| Miles D. White         | 1,044,270,331 | 51,077,556     | 205,672,438      |

(2) The shareholders ratified the appointment of Ernst & Young LLP as Abbott's auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:

| For           | Against   | Abstain   | Broker Non-Votes |
|---------------|-----------|-----------|------------------|
| 1,292,626,550 | 6,402,570 | 1,991,205 | 0                |

(3) The shareholders voted to approve the compensation of Abbott's named executive officers listed in the proxy statement for the 2016 annual meeting, with 94.01 percent of the votes cast voting For the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

| For           | Against    | Abstain    | Broker Non-Votes |
|---------------|------------|------------|------------------|
| 1,029,769,849 | 55,384,958 | 10,193,080 | 205,672,438      |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ABBOTT LABORATORIES**

Date: May 4, 2016

By:

/s/ Brian B. Yoor  
Brian B. Yoor  
Senior Vice President, Finance  
and Chief Financial Officer